Clinical Trials
23 trialsVinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
Second Affiliated Hospital of Soochow University
EVIDENCE
Betta Pharmaceuticals Co., Ltd.
To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Shanghai Chest Hospital
EPIC
University of Turin, Italy
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
Xinqiao Hospital of Chongqing
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
Betta Pharmaceuticals Co., Ltd.
GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients
Peking Union Medical College Hospital
Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations
Chinese Lung Cancer Surgical Group
First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
TIE
LungenClinic Grosshansdorf
Study for Patients With Non Small Cell Lung Cancer (NSCLC)
Charite University, Berlin, Germany
Random Trial for Elderly Patients With NSCLC
Inje University